Venus Remedies Limited (VENUSREM) AI Stock Analysis

• Market Cap: ₹5.86B
• Dividend Yield: N/A
• Average Volume (3M): 1.72K
• Price to Earnings (P/E): 10.9
• Beta (1Y): 0.73
• Revenue Growth: 9.15%
• EPS Growth: 88.32%
• Country: IN
• Employees: 1,187
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 7.18
• Shares Outstanding: 13,366,988
• 10 Day Avg. Volume: 1,769
• 30 Day Avg. Volume: 1,721
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹483.00
• Price Target Upside: 10.10% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: ₹483.00 ▲(10.10% Upside)

Venus Remedies Limited's strong financial performance is the most significant factor, supported by robust revenue growth and solid cash flow management. The technical analysis indicates a bearish trend, which slightly offsets the positive financial outlook. Valuation is reasonable, suggesting potential for growth, but the lack of earnings call data and corporate events limits further insights.

Venus Remedies Limited Business Overview & Revenue Model

Company Description

Venus Remedies Limited (VENUSREM) is a globally recognized pharmaceutical company specializing in the research, development, and manufacturing of a wide range of generic and branded pharmaceutical products. The company focuses on several key therapeutic areas, including oncology, anti-infectives, and critical care medications, catering to both domestic and international markets. Venus Remedies is known for its innovative approach to drug delivery systems and commitment to quality standards, which has earned it a strong presence in over 70 countries worldwide.

How the Company Makes Money

Venus Remedies Limited generates revenue primarily through the sale of its pharmaceutical products, which include both generic and branded medications. The company's revenue streams are diversified across various therapeutic segments, with significant contributions coming from oncology, anti-infectives, and critical care drugs. Venus Remedies leverages its extensive distribution network and strong partnerships with healthcare providers, hospitals, and pharmacies to ensure wide market reach. Additionally, the company's focus on research and development enables it to introduce new and innovative products, contributing to sustained growth and competitive advantage in the pharmaceutical industry.

Venus Remedies Limited Financial Statement Overview

Summary

Venus Remedies Limited shows strong financial performance with consistent revenue growth, robust profit margins, and effective cash flow management. The company maintains financial stability with a low reliance on debt and a solid equity base, indicating a solid financial foundation and potential for sustained growth.

Income Statement

Venus Remedies Limited has demonstrated strong revenue growth over the years, with a significant increase from 2020 to 2025. The company maintains a healthy Gross Profit Margin, indicating efficient production and cost management. The Net Profit Margin has improved significantly compared to earlier losses, reflecting enhanced operational efficiency and profitability. The EBIT and EBITDA margins are solid, showcasing robust earnings performance before interest, taxes, and non-cash expenses.

Balance Sheet

The company displays a strong equity position with a high Equity Ratio, suggesting financial stability and a low reliance on debt. The Debt-to-Equity Ratio is favorable, indicating low financial leverage and reduced risk of financial distress. Return on Equity has shown consistent improvement, reflecting effective use of shareholders' equity in generating profits.

Cash Flow

Venus Remedies Limited exhibits strong cash flow performance, with a significant positive Free Cash Flow trend, indicating good cash generation after capital expenditures. The Operating Cash Flow to Net Income Ratio is robust, highlighting efficient conversion of earnings into cash. There is a significant increase in Free Cash Flow over the years, underscoring the company's strong cash-generating capabilities.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.48B	6.48B	5.56B	5.91B	5.99B	5.48B
Gross Profit	1.75B	1.66B	2.25B	2.18B	2.00B	1.96B
EBITDA	820.40M	944.10M	605.10M	711.80M	625.77M	545.57M
Net Income	348.50M	453.20M	265.70M	284.91M	407.24M	617.65M
Balance Sheet
Total Assets	0.00	7.16B	6.01B	6.27B	5.80B	5.56B
Cash, Cash Equivalents and Short-Term Investments	1.34B	1.64B	749.20M	838.05M	453.11M	288.79M
Total Debt	0.00	16.90M	422.90M	413.25M	428.45M	513.18M
Total Liabilities	-4.94B	1.55B	1.41B	1.39B	1.39B	1.56B
Stockholders Equity	4.94B	5.61B	4.60B	4.88B	4.40B	4.00B
Cash Flow
Free Cash Flow	0.00	812.90M	288.02M	278.40M	272.94M	1.25B
Operating Cash Flow	0.00	909.20M	366.20M	372.85M	410.01M	1.33B
Investing Cash Flow	0.00	-807.90M	-508.30M	-72.09M	-166.26M	557.16M
Financing Cash Flow	0.00	-9.50M	-5.70M	-10.83M	-94.77M	-1.62B

Venus Remedies Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 438.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VENUSREM, the sentiment is Negative. The current price of 438.7 is below the 20-day moving average (MA) of 451.27, below the 50-day MA of 481.75, and above the 200-day MA of 378.88, indicating a neutral trend. The MACD of -9.17 indicates Negative momentum. The RSI at 40.29 is Neutral, neither overbought nor oversold. The STOCH value of 41.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VENUSREM.

Venus Remedies Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	67 Neutral	₹5.86B	10.92	―	―	9.15%	88.32%
INDSWFTLAB	58 Neutral	₹6.02B	2.90	21.35%	―	-68.96%	-30.30%
KILITCH	57 Neutral	₹5.92B	19.89	13.20%	―	37.51%	122.52%
MEDICAMEQ	54 Neutral	₹4.13B	41.20	3.34%	0.33%	-9.90%	33.18%
ZIMLAB	54 Neutral	₹3.57B	38.06	4.82%	―	-3.36%	-47.58%
NECLIFE	43 Neutral	₹3.26B	-1.81	-11.89%	―	-3.41%	-3028.44%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Venus Remedies Limited Corporate Events

Venus Remedies Announces AGM Notice Publication

Venus Remedies Limited has announced a newspaper publication regarding its Annual General Meeting (AGM) notice. This announcement is part of the company’s regulatory compliance under Regulation 30 of the Listing Obligations and Disclosure Requirements (LODR). The publication ensures that stakeholders are informed about the AGM, which is a critical event for discussing the company’s performance and future strategies.